May. 29 at 12:50 PM
$AUTL ASCO 2026
Rapid Oral Abstract: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.
Session Date and Time: May 30, 2026; 1:15 – 2:45PM CDT
Session Room: E450a
Abstract Number: 6517
Presentation time: 2:27 – 2:33pm CDT
Presenting Author: Jae Park, MD, Director, Adult ALL Program | Acting Chief, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Summary: A post-hoc analysis of the Phase Ib/II FELIX study (NCT04404660) was conducted, evaluating the efficacy and safety of obe-cel in patients with relapsed or refractory (r/r) B-ALL, by EMD status at lymphodepletion (LD). Obe-cel treatment demonstrated favorable response and safety outcomes in patients with and without EMD in the FELIX trial. Overall, these findings suggest a positive benefit–risk profile for obe-cel, including for patients with adverse risk features, specifically EMD at LD.
